S

Sinil Pharmaceutical Co Ltd
KOSDAQ:012790

Watchlist Manager
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
Watchlist
Price: 6 250 KRW -0.79%
Market Cap: 74.9B KRW

Relative Value

The Relative Value of one Sinil Pharmaceutical Co Ltd stock under the Base Case scenario is 7 536.49 KRW. Compared to the current market price of 6 250 KRW, Sinil Pharmaceutical Co Ltd is Undervalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
7 536.49 KRW
Undervaluation 17%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
79
vs Industry
73
Median 3Y
0.9
Median 5Y
1.1
Industry
2.6
vs History
63
vs Industry
43
Median 3Y
6.2
Median 5Y
7.1
Industry
21.7
vs History
68
vs Industry
50
Median 3Y
4.8
Median 5Y
6.9
Industry
16.7
vs History
53
vs Industry
35
Median 3Y
6
Median 5Y
9.8
Industry
23.1
vs History
92
vs Industry
73
Median 3Y
0.6
Median 5Y
0.7
Industry
2.2
vs History
90
vs Industry
86
Median 3Y
0.6
Median 5Y
0.8
Industry
2.9
vs History
90
vs Industry
82
Median 3Y
1.4
Median 5Y
1.9
Industry
5.5
vs History
92
vs Industry
50
Median 3Y
3.3
Median 5Y
4.1
Industry
13.2
vs History
82
vs Industry
48
Median 3Y
3.9
Median 5Y
5
Industry
16.8
vs History
73
vs Industry
52
Median 3Y
2.7
Median 5Y
5.2
Industry
15.9
vs History
58
vs Industry
39
Median 3Y
3.5
Median 5Y
7.5
Industry
19.2
vs History
92
vs Industry
79
Median 3Y
0.5
Median 5Y
0.6
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Sinil Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
72.2B KRW 0.9 6.3 1.8 3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.1 36.9 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
213B GBP 4.9 30.6 108.9 159.4
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
261.3B USD 4.1 13.7 9.8 11.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
141.5B USD 2.3 14.4 7.4 10.1
P/E Multiple
Earnings Growth PEG
KR
S
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
Average P/E: 22.3
6.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.1
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.6
38%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.7
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
4%
3.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.4
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
S
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
Average EV/EBITDA: 399.3
1.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
4%
3
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.8
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
2%
5
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
S
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
Average EV/EBIT: 1 710.7
3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
159.4
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.6
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3